期刊文献+

先心病合并肺动脉高压患儿介入封堵术及药物干预后血浆脑钠肽血管内皮素的变化 被引量:1

暂未订购
导出
摘要 目的探讨小儿先心病(congenitalheartdisease,CHD)伴肺动脉高压(pulmonaryarterialhyper-tension,PAH)经导管封堵术前后患儿血脑钠肽(brainnatriureticepeptide,BNP)、血管内皮素1(ET-1)的变化及西地那非的干预作用。方法选择2010年1月至2011年12月在我院行先天性心脏病介入封堵术的患儿60例,肺动脉收缩压30mmHg<(SPAP)<70mmHg,3岁<年龄<13岁,随机分为2组:A组(西地那非组,n=30)给予口服西地那非(每次1mg/kg,每天2次);B组(无药物干预组,n=30)。2组患儿年龄、肺动脉压无显著性差异。分别于封堵术前当天及术后第3天、术后1个月抽血检测BNP、ET-1浓度。药物干预组患儿自术后3天抽血后开始服药。结果 1)封堵术前,A、B 2组血BNP、ET-1水平比较无明显差异(P>0.05);行封堵术后,A组血BNP、ET-1水平较封堵前下降,差异有统计学意义(P<0.05),B组血BNP、ET-1水平较封堵前下降,差异有统计学意义(P<0.05)。2)术后1月,药物干预后患儿血BNP、ET-1浓度均较用药前显著降低,差异有显著统计学意义(P<0.01)。结论介入治疗术后,CHD伴PAH患儿的血BNP、ET-1浓度较术前降低。西地那非可使其得到改善。血BNP、ET-1水平测定可能成为CHD患儿经导管封堵治疗判断预后的重要标志物。
出处 《济宁医学院学报》 2012年第2期117-118,121,共3页 Journal of Jining Medical University
  • 相关文献

参考文献6

  • 1Dasgupta A,Chow L,Tso G,et al. Stability of NT-proBNP in serum specmiens collected in Becton Dickinson Vacutainer (SST)tubes[J]. Clin Chem,2003,49(6 Pt 1):958-960.
  • 2Kunii Y,Kamada M,Ohtsuki S,et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease[J]. Acta Med Okaya- ma,2003,57(4) :191-197.
  • 3Book WM, Hott BJ, McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ven- tricular failure[J]. Am J Cardiol, 2005,95(4) : 545-546.
  • 4Salzberg SP, Filsoufi F, Anyanwu A, et al. Hiigh--risk mitral valve surgery: perioperative hemodynamie optimization with nesiritide(BNP) [J]. Ann Thorac Surg,2005,80(2) :502-506.
  • 5Takahashi T, Kanda T, Sumino H, et al. Type V phosphodi- esterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pul- monary arteries in rats with monoerotaline-induced pulmona- ry hypertension[J]. Res Exp Med,1998,197(6):319-328.
  • 6赵翠芬,夏伟,王玉玮,杨杰,杨兴季.先天性心脏病肺动脉高压患儿肺组织内皮素-1与胶原合成关系的研究[J].临床儿科杂志,2006,24(5):374-376. 被引量:4

二级参考文献10

  • 1赵翠芬,夏伟,刘月欣,刘之静,杨杰,王玉玮,杨兴季.BQ_(123)对左向右分流肺动脉高压大鼠肺组织Ⅰ、Ⅲ型胶原合成的影响[J].山东大学学报(医学版),2005,43(3):223-226. 被引量:3
  • 2Yanagisawa M, Kurihara H, Kimara S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988,322:411 - 415.
  • 3Egito ES,Aiello VD,Bosisio IB,et al. Vascular remodeling process in reversibility of pulmonary arterial hypertension secondary to congenital heart disease.Pathol Res Pract, 2003,199(8) : 521 - 532.
  • 4Nicod LP. Pulmonary hypertension. Swiss Med Wkly,2003,133(7 - 8) : 103 - 110.
  • 5Ye C, Rabinovitch M. New developments in the pulmonary circulation in children. Curr Opin Cardiol, 1992,7(1) :124- 133.
  • 6Reichenberger F, Pepke-Zaba J, Mcneil K, et al.Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax, 2003, 58(9) : 797 - 800.
  • 7Jia B, Zhang S, Chen Z, et al. Plasma endothelin-1 concentrations in children with congenital heart defects. Minerva Pediatr, 1998,50(4) : 99- 103.
  • 8Hoeper MM.Pulmonary hypertension in collagen vascular disease. Rur Respir J, 2002,19(3) :571 - 576.
  • 9Lee KM, Tsai KY, Wang N, et al. Extracellular matrix and pulmonary hypertension:control of vascular smooth muscle cell contractility.Am J Physiol, 1998, 274(1 pt2) : H76- H82.
  • 10孟国伟,郭兰敏,邹承伟,李德才,王安彪.先心病肺高压病儿血浆内皮素与肺组织I、III型胶原含量的相关研究[J].中华胸心血管外科杂志,2003,19(6):343-345. 被引量:8

共引文献3

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部